Lisa Sommerhalder holds a Bachelor’s degree in Pharmacy from the University of Bern and is currently pursuing an MSc in Drug Science at the University of Basel. She joined the SCAHT in December 2025 to conduct her Master's thesis. Her research contributes to the development of an Adverse Outcome Pathway (AOP) regarding the impact of LXR agonism on neurodevelopment.